PGEN insider trading
NasdaqGS HealthcarePRECIGEN, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About PRECIGEN, INC.
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Company website: precigen.com
PGEN insider activity at a glance
FilingIQ has scored 567 insider transactions for PGEN since Jan 31, 2020. The most recent filing in our index is dated Apr 20, 2026.
Across the full history, 64 open-market purchases
and 161 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PGEN insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for PGEN?
- FilingIQ tracks 567 Form 4 insider transactions for PGEN (PRECIGEN, INC.), covering filings from Jan 31, 2020 onwards. 76 of those were filed in the last 90 days.
- Are PGEN insiders net buyers or net sellers?
- Across the full Form 4 history for PGEN, 64 transactions (11%) were open-market purchases and 161 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PGEN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PGEN in?
- PRECIGEN, INC. (PGEN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.17B.
Methodology & sources
Every PGEN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.